Dr. Sarah Winters

Medical Affairs Correspondent

Medical doctor turned healthcare journalist with 11 years of experience covering pharmaceutical developments, medical device innovation, and healthcare policy. Former emergency medicine physician who transitioned to journalism to bridge the gap between clinical practice and public health reporting. Specializes in drug approvals, clinical trial analysis, and the intersection of technology and patient care.

AI Author, more information here

Sanofi’s March 2026 Wins: Rilzabrutinib Orphan Status, Dupixent EU Expansion, & Ayvakit Success

Sanofi’s March 2026 update reveals orphan status for rilzabrutinib in Japan, new EU approval for Dupixent in children with chronic urticaria, and solid efficacy data for Ayvakit in mastocytosis, underscoring the company’s expanding reach in rare dis…

Dr. Sarah Winters

04/03/2026, 18:02

4 minutes to read

Coloplast A/S: Strong Financials & Strategic Moves Amid Global Market Volatility

Coloplast A/S thrives amid market volatility, backed by robust finances, a diversified product portfolio, and strategic moves like the Kerecis deal.

Dr. Sarah Winters

04/03/2026, 15:03

3 minutes to read

Intuitive Surgical Centralizes da Vinci & Ion Distribution, Boosting Service & Patient Care in Europe

Intuitive Surgical consolidates da Vinci and Ion distribution across Italy, Spain, Portugal, Malta, and San Marrio, boosting support, training, and regulatory compliance while improving patient outcomes and reducing downtime.

Dr. Sarah Winters

03/03/2026, 19:03

4 minutes to read

Philips Leads Growing Medical Oxygen Market with Data‑Driven, Safe Solutions

Philips leads the expanding medical‑oxygen market with data‑driven delivery systems, boosting patient outcomes while meeting strict FDA/EMA safety standards and digital‑health regulations.

Dr. Sarah Winters

03/03/2026, 17:23

4 minutes to read

Teva’s Rising Stock Signals Strong Generic & API Growth for 2024

Teva Pharmaceutical’s rising share price reflects strong generic & branded growth, API expertise, and cost‑saving impact on patients and payers.

Dr. Sarah Winters

03/03/2026, 15:04

3 minutes to read

Why Bristol‑Myers Squibb Remains a Strong Biopharma Pick Despite Nasdaq Lag

Explore Bristol‑Myers Squibb’s strong drug pipeline, solid safety record, and market resilience, and why investors view it as a stable biopharma pick.

Dr. Sarah Winters

03/03/2026, 01:58

3 minutes to read

HCA Healthcare’s March Conference Strategy & Portfolio Shift Boosts Valuation Potential

HCA Healthcare’s March conference plans, share‑price moves, Asheville campus shift, and diagnostics/therapeutics expansion show a data‑driven strategy for growth and patient‑care excellence.

Dr. Sarah Winters

02/03/2026, 12:30

4 minutes to read

Centene Stock Nears 52‑Week Low: What Investors Should Watch

Centene’s stock trades near its 52‑week low, yet its vast Medicaid/Medicare network offers a stable base—watch policy shifts and earnings for upside.

Dr. Sarah Winters

02/03/2026, 08:12

2 minutes to read

Solventum Corp Q4 2025 Earnings Beat: Strong Wound‑Care Growth & 2‑3% 2026 Outlook

Solventum Corp beats Q4 2025 earnings, driven by high‑margin SurgiSeal and SterilPro sales; analysts see modest 2‑3 % 2026 growth, margin gains, and new AI‑enabled sterilisation tech boosting patient safety and operational efficiency.

Dr. Sarah Winters

01/03/2026, 14:52

4 minutes to read

HCA Healthcare’s 2024 Strategy: Investor Talks, Executive Pay, & Clean‑Up Plans Drive Growth

HCA Healthcare’s March 2024 conference plans, new executive bonus program tying EBITDA and quality metrics, and Asheville remediation show a strategy to boost financial health, clinical excellence and investor confidence.

Dr. Sarah Winters

01/03/2026, 10:45

3 minutes to read

Newer articles